Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

Chronic myeloid leukemia (CML) is the consequence of a single balanced translocation that produces the BCR-ABL fusion oncogene which is detectable in over 90% of patients at presentation. The BCR-ABL inhibitor imatinib mesylate (IM) has improved survival in all phases of CML and is the standard of c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Swords, Ronan, Mahalingam, Devalingam, Padmanabhan, Swaminathan, Carew, Jennifer, Giles, Francis
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2009
Schlagworte:
Review
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2769239/
https://ncbi.nlm.nih.gov/pubmed/19920925
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge